Core Viewpoint - Serina Therapeutics has successfully closed the second tranche of a $10 million equity financing, enabling the advancement of its investigational drug SER-252 into Phase 1 clinical trials for advanced Parkinson's disease patients in the second half of 2025 [1][3]. Financing Details - The second tranche involved a $5 million investment from strategic shareholder JuvVentures, with Serina issuing 500,000 shares at $10 per share, reflecting a 113% premium over the closing price on January 31, 2025 [2]. - Additionally, warrants for up to 755,728 shares at an exercise price of $18.00 per share were issued to JuvVentures [2]. Product Development - SER-252 (POZ-apomorphine) is designed to provide continuous dopaminergic stimulation (CDS), which can reduce levodopa-related motor complications in advanced Parkinson's patients [4]. - The drug leverages Enable Injections' enFuse™ wearable drug delivery platform for enhanced patient comfort and convenience [4]. Technology Overview - Serina's proprietary POZ Platform™ utilizes a synthetic polymer to improve drug loading control and release precision, aiming to maintain stable blood levels of therapeutic agents [5]. - The POZ technology has potential applications across various drug delivery formulations, including a non-exclusive license agreement with Pfizer for lipid nanoparticle drug delivery [6]. Company Background - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases, utilizing its POZ Platform™ to enhance the efficacy and safety profiles of various therapeutic modalities [7].
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients